CXCR4 and myeloid sarcoma: a sphingosine-1-phosphate receptor (S1PR) (Approved for MS. Sequesters lymphocytes in lymph nodes. Reduces annualized relapse rate reduced by 39% (1.25 mg) and 52% (0.5 mg). Reduces CXCR4-mediated B cell migration.)